classical Hodgkin’s lymphoma

April 13, 2020April 13, 2020

Keytruda Prolongs Life Without Disease Worsening in Classical Hodgkin’s Lymphoma, Interim Data Confirm

News

Keytruda (pembrolizumab) significantly extends survival without disease worsening in adults with relapsed or refractory classical Hodgkin’s Lymphoma (cHL), compared to treatment with Adcetris (brentuximab vedotin), interim data from a Phase ... Read more

May 14, 2019

Health Canada Approves Adcetris-Chemo for Advanced Classical Hodgkin’s Lymphoma

News

Health Canada has approved Seattle Genetics‘ submission requesting approval of Adcetris (brentuximab vedotin) in combination with standard chemotherapy as a frontline treatment for patients with advanced (stage IV) classical Hodgkin’s lymphoma. ... Read more

September 6, 2018

New Drug Application for Investigational Hodgkin’s Lymphoma Therapy Tislelizumab Accepted in China

News

China’s regulatory agency recently accepted BeiGene’s new drug application (NDA) for tislelizumab, its investigational immune checkpoint inhibitor, for the potential treatment of patients with classical Hodgkin’s lymphoma who failed to respond or whose disease ... Read more

July 27, 2018

BeiGene’s Therapy Candidate Appears to Eliminate Tumors in Half of Hodgkin’s Patients in Phase 2 Trial

News

BeiGene‘s immunotherapy candidate tislelizumab was shown to eliminate tumors in 50% of patients with classical Hodgkin’s lymphoma who had failed to respond to their most recent treatment, according to preliminary results of a Phase ... Read more

May 22, 2018May 22, 2018

Adcetris-Dacarbazine Combo is Effective in Elderly Hodgkin’s Patients, Study Finds

News

A combination of Adcetris (brentuximab vedotin) and dacarbazine chemotherapy may be a suitable option for frail, elderly patients with classical Hodgkin’s lymphoma who are ineligible for standard treatment, according to data ... Read more

May 10, 2018

UK Agency Recommends 3 New Blood Cancer Therapies, Including Adcetris for Lymphoma

News

The United Kingdom’s National Institute for Health and Care Excellence (NICE) recently recommended that three new blood cancer therapies be covered by the National Health Service (NHS) — Trisenox (arsenic trioxide), Rydapt ... Read more

March 22, 2018

FDA Approves Adcetris, Chemotherapy Combo for Advanced Classical Hodgkin’s Lymphoma

News

The U.S. Food and Drug Administration approved the combination of Seattle Genetics’ Adcetris (brentuximab vedotin) with chemotherapy for the treatment of adults with previously untreated stage 3 or 4 classical Hodgkin’s ... Read more

November 9, 2017November 9, 2017

Seattle Genetics Asks FDA to Accept Adcetris as Treatment for Hodgkin’s Lymphoma

News

Seattle Genetics has asked the U.S. Food and Drug Administration (FDA) to expand the label for Adcetris (brentuximab vedotin) to be used in combination with chemotherapy as a first-line treatment ... Read more

October 20, 2017October 21, 2017

Researchers Identify Enzyme as New Target for Treating Classical Hodgkin’s Lymphoma

News

An enzyme called monoamine oxidase-A (MAO-A) contributes to the growth of classical Hodgkin’s lymphoma cells but not other lymphoma cells, a study reports. It also indicated that a combination of ... Read more

August 29, 2016August 29, 2016

Opdivo Shows Potential in Specific Hodgkin’s Lymphoma Patients Whose Disease Progressed After Bone Marrow Transplant

News

Patients with classical Hodgkin’s lymphoma who progressed after receiving autologous hematopoietic stem cell transplant (HSCT) and treatment with Adcetris (brentuximab vedotin) may benefit from the PD-1 inhibitor Opdivo (nivolumab), according ... Read more